{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:51:34Z","timestamp":1791993094375,"version":"4.4.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Androgenetic alopecia (AGA) is the most common cause of progressive hair loss in men and women and is associated with significant psychosocial distress. Platelet-rich plasma (PRP) is a regenerative therapy that stimulates follicular activity, angiogenesis, and dermal papilla activation through growth factor release.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This prospective randomized evaluator-blinded clinical trial evaluated the long-term efficacy and safety of autologous nonactivated PRP (A-PRP) delivered through a standardized mechanical and controlled infiltration protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between January 2015 and January 2025, 234 patients with AGA were enrolled, including 135 men (Norwood\u2013Hamilton I-IV) and 99 women (Ludwig I-II); 25 patients had previous confirmed coronavirus disease 2019 (COVID-19) infection. Patients received 3 A-PRP sessions at 30-day intervals with intradermal administration of 0.2\u2005mL\/cm2. Hair density (HD), hair thickness (HT), and total hair count (HC) were assessed by computerized trichoscopy and phototrichogram analysis at baseline, 12, 36, 60, and 120 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 12 months, HD increased by 31.4%, HT by 26.8%, and HC by 29.7% compared with baseline (P &amp;lt; .001). HD remained above baseline at 36 months (+24.1%) and 60 months (+17.3%). At 120 months, patients receiving maintenance treatment showed an 11.2% improvement. Female patients demonstrated greater preservation of hair shaft diameter. No significant differences were observed according to previous COVID-19 infection, and no severe adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Standardized A-PRP infiltration provides a safe and effective regenerative approach for AGA, with maintained clinical improvement during long-term follow-up. These findings support the role of standardized delivery protocols in improving reproducibility and therapeutic consistency in regenerative hair restoration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence: 2 (Therapeutic)<\/jats:title>\n                    <jats:p>For image description, please refer to the figure legend and surrounding text.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/asj\/sjag181","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:27:46Z","timestamp":1788334066000},"source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Clinical Outcomes of Autologous Nonactivated Platelet-Rich Plasma Delivered Through Mechanical and Controlled Infiltration in Male and Female Androgenetic Alopecia: A 10-Year Prospective Randomized Evaluator-Blinded Study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3123-3977","authenticated-orcid":false,"given":"Pietro","family":"Gentile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2026101411365814700_sjag181-B1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmhg.2004.09.016","article-title":"Male androgenetic alopecia","volume":"1","author":"Sinclair","year":"2004","journal-title":"J Men Health Gend"},{"key":"2026101411365814700_sjag181-B2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1046\/j.1365-2133.2001.04018.x","article-title":"Hair density, hair diameter and the prevalence of female pattern hair loss","volume":"144","author":"Birch","year":"2001","journal-title":"Br J Dermatol"},{"key":"2026101411365814700_sjag181-B3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/187221312800166859","article-title":"Minoxidil use in dermatology, side effects and recent patents","volume":"6","author":"Rossi","year":"2012","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"2026101411365814700_sjag181-B4","doi-asserted-by":"publisher","first-page":"739e","DOI":"10.1097\/PRS.0000000000010076","article-title":"Autologous platelet-rich plasma treatment for androgenic alopecia: a systematic review and meta-analysis of clinical trials","volume":"151","author":"Papakonstantinou","year":"2023","journal-title":"Plast Reconstr Surg"},{"key":"2026101411365814700_sjag181-B5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14712598.2020.1724951","article-title":"Autologous activated platelet-rich plasma (AA-PRP) and non-activated (A-PRP) in hair growth: a retrospective, blinded, randomized evaluation in androgenetic alopecia","volume":"20","author":"Gentile","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026101411365814700_sjag181-B6","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3390\/ijms21082702","article-title":"Systematic review of platelet-rich plasma use in androgenetic alopecia compared with Minoxidil\u00ae, finasteride\u00ae, and adult stem cell-based therapy","volume":"21","author":"Gentile","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026101411365814700_sjag181-B7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bjps.2021.11.004","article-title":"Systematic review: the platelet-rich plasma use in female androgenetic alopecia as effective autologous treatment of regenerative plastic surgery","volume":"75","author":"Gentile","year":"2022","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2026101411365814700_sjag181-B8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/cells8050466","article-title":"Advances in regenerative stem cell therapy in androgenic alopecia and hair loss: Wnt pathway, growth-factor, and mesenchymal stem cell signaling impact analysis on cell growth and hair follicle development","volume":"8","author":"Gentile","year":"2019","journal-title":"Cells"},{"key":"2026101411365814700_sjag181-B9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.5966\/sctm.2015-0107","article-title":"The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial","volume":"4","author":"Gentile","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"2026101411365814700_sjag181-B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020408","article-title":"Evaluation of not-activated and activated PRP in hair loss treatment: role of growth factor and cytokine concentrations obtained by different collection systems","volume":"18","author":"Gentile","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026101411365814700_sjag181-B11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"2026101411365814700_sjag181-B12","doi-asserted-by":"publisher","DOI":"10.3791\/56406","article-title":"Mechanical and controlled PRP injections in patients affected by androgenetic alopecia","author":"Gentile","year":"2018","journal-title":"J Vis Exp"},{"key":"2026101411365814700_sjag181-B13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/760709","article-title":"The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histomorphometric evaluation","volume":"2014","author":"Cervelli","year":"2014","journal-title":"Biomed Res Int"},{"key":"2026101411365814700_sjag181-B14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jaad.2018.09.033","article-title":"Treatment of male pattern alopecia with platelet-rich plasma: a double-blind controlled study with analysis of platelet number and growth factor levels","volume":"80","author":"Rodrigues","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026101411365814700_sjag181-B15","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jaad.2020.07.006","article-title":"Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: a randomized controlled trial","volume":"83","author":"Hausauer","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026101411365814700_sjag181-B16","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jaad.2020.06.1021","article-title":"The effect of platelet-rich plasma on female androgenetic alopecia: a randomized controlled trial","volume":"83","author":"Dubin","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026101411365814700_sjag181-B17","doi-asserted-by":"publisher","first-page":"NP1659","DOI":"10.1093\/asj\/sjab236","article-title":"The effects of lower vs higher cell number of platelet-rich plasma (PRP) on hair density and diameter in androgenetic alopecia (AGA): a randomized, double-blinded, placebo, parallel-group half-scalp IRB-approved study","volume":"41","author":"Sasaki","year":"2021","journal-title":"Aesthet Surg J"},{"key":"2026101411365814700_sjag181-B18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.joms.2003.12.003","article-title":"Platelet-rich plasma: evidence to support its use","volume":"62","author":"Marx","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2026101411365814700_sjag181-B19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/DSS.0000000000000665","article-title":"Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia","volume":"42","author":"Alves","year":"2016","journal-title":"Dermatol Surg"},{"key":"2026101411365814700_sjag181-B20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/DSS.0000000000000883","article-title":"Double-blind, placebo-controlled pilot study on the use of platelet-rich plasma in women with female androgenetic alopecia","volume":"42","author":"Puig","year":"2016","journal-title":"Dermatol Surg"},{"key":"2026101411365814700_sjag181-B21","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1111\/jocd.14005","article-title":"Efficacy of platelet-rich plasma in the treatment of androgenetic alopecia: a randomized clinical trial","volume":"20","author":"Mapar","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"2026101411365814700_sjag181-B22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1524-4725.2012.02394.x","article-title":"Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth","volume":"38","author":"Li","year":"2012","journal-title":"Dermatol Surg"},{"key":"2026101411365814700_sjag181-B23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjd.12397","article-title":"A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata","volume":"169","author":"Trink","year":"2013","journal-title":"Br J Dermatol"},{"key":"2026101411365814700_sjag181-B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5966\/sctm.2012-0041","article-title":"Promotion of hair growth by platelet-rich plasma through activation of \u03b2-catenin signaling pathway","volume":"1","author":"Li","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"2026101411365814700_sjag181-B25","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1524-4725.2011.02123.x","article-title":"Enhanced effect of platelet-rich plasma containing a new carrier on hair growth","volume":"37","author":"Takikawa","year":"2011","journal-title":"Dermatol Surg"},{"key":"2026101411365814700_sjag181-B26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1051\/ject\/200638174","article-title":"Platelet-rich plasma and platelet gel: a review","volume":"38","author":"Everts","year":"2006","journal-title":"J Extra Corpor Technol"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjag181\/70910853\/sjag181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjag181\/70910853\/sjag181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:37:06Z","timestamp":1791992226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/advance-article\/doi\/10.1093\/asj\/sjag181\/8779657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/asj\/sjag181","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"sjag181"}}